

Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

<https://marketpublishers.com/r/H554E2B786AEN.html>

Date: July 2013

Pages: 164

Price: US\$ 2,090.00 (Single User License)

ID: H554E2B786AEN

Abstracts

Hepatitis C Market Overview

Hepatitis C market by 2018 is expected to grow more than 3 times from its current market size of 2012. Hepatitis C virus (HCV) infection is a complex public health problem, characterized by a high prevalence of chronic infection, an increasing burden of HCV-associated disease, low rates of testing, treatment and the prospect of increasing incidence associated with the epidemic of injection drug use. Hepatitis C is a leading cause of chronic liver disease, end-stage cirrhosis and liver cancer. Because of the slow progression and asymptomatic character of the infection, many people are unaware of having it. As a consequence, the infection is often diagnosed at a late stage when treatment options are limited. As no effective vaccine against the Hepatitis C virus (HCV) has been discovered so far the market is driven by therapeutics. The increase in the prevalence of the disease and the availability of new first-in-class therapies with better safety and efficacy profiles are expected to drive the growth of the HCV market. The growth in HCV drugs market is primarily attributed to high unmet need in the market which is expected to be fulfilled by strong pipeline candidates. Low levels of awareness and knowledge about HCV have been identified as a formidable challenge to prevention and care.

Renub Research study titled "Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide" provides a comprehensive assessment of the fast-evolving, high-growth of Hepatitis sector. This 164 page report with 25 Figures and 2 Tables studies the Hepatitis C Drug Market Landscape. This report contains 7 chapters.

- A. Hepatitis C Drugs Market & Forecast (Chapter 2)
- B. Hepatitis C Approved Drugs Sales & Forecast (Chapter 3)
- C. Hepatitis C Deals & Acquisitions (Chapter 4)
- D. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter 5)
- E. Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter 6)
- F. Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)

Hepatitis C – Approved Drugs sales & Forecast Analysis (To 2016) (Chapter No. 3)

- 1. Pegasys
- 2. Pegintron
- 3. Incivek
- 4. Victrelis

Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase III) (Chapter No. 5)

- 1. Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)
- 2. Faldaprevir (BI 201335) (Company: Boehringer Ingelheim)
- 3. Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)
- 4. PEG-Interferon Lambda (Company: Bristol-Myers Squibb)
- 5. Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)
- 6. Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)
- 7. BI-207127 (Company: Boehringer Ingelheim)
- 8. ABT-450/r (Ritonavir) (Company: Abbott Laboratories)
- 9. ABT-267 (Company: Abbott Laboratories)
- 10. ABT-072/333 (Company: Abbott Laboratories)
- 11. Alisporivir (Company: Novartis)

Hepatitis C – Pipeline Drugs Clinical Trials (Drugs in Phase II) (Chapter No. 6)

- 1. Mericitabine (RG-7128) (Company: Roche)
- 2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)
- 3. GS-9256 (Company: Gilead Sciences)
- 4. GS-9451 (Company: Gilead Sciences)
- 5. MK-5172 (Company: Merck)
- 6. Sovaprevir (ACH-1625) (Company: Achillion)
- 7. IDX-320 (Company: Idenix)
- 8. MK-8742 (Company: Merck)

9. ACH-3102 (Company: Achillion Pharmaceuticals, Inc)
10. IDX-719 (Company: Idenix)
11. PPI-668 (Company: Presidio Pharmaceuticals)
12. Setrobuvir (ANA-598) (Company: Roche)
13. VX-222 (Company: Vertex Pharmaceuticals)
14. GS-9669 (Company: Gilead Sciences)
15. GS-9190 (Tegobuvir) (Company: Gilead Sciences)
16. BMS-791325 (Company: Bristol-Myers Squibb)

Hepatitis C - Pipeline Drugs Sales Forecast (Chapter 7)

1. Simeprevir (TMC 435)
2. Faldaprevir (BI 201335) (Boehringer Ingelheim)
3. Asunaprevir (BMS-650032)
4. Sofosbuvir (PSI-7977 or GS-7977)
5. Daclatasvir (BMS-790052)
6. ABT-450/r (Ritonavir)
7. ABT-072/333
8. Alisporivir
9. Mericitabine (RG-7128)
10. Danoprevir (RG7227)
11. GS-9256
12. Setrobuvir (ANA-598)
13. VX-222
14. GS-9190 (Tegobuvir)
15. BMS-791325

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephone interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites,

Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Contents

1. EXECUTIVE SUMMARY

2. HEPATITIS C DRUGS – MARKET & FORECAST

3. HEPATITIS C – APPROVED DRUGS SALES & FORECAST

3.1 Pegasys Sales and Forecast

3.2 Peginteron Sales and Forecast

3.3 Incivek Sales and Forecast

3.4 Victrelis Sales and Forecast

4. HEPATITIS C – DEALS & ACQUISITIONS

5. HEPATITIS C – PIPELINE DRUGS CLINICAL TRIALS (DRUGS IN PHASE III)

5.1 Simeprevir (TMC 435) (Company: Janssen Pharmaceutical)

5.1.1 Phase I

5.1.2 Phase II

5.1.3 Phase III

5.2 Faldaprevir (BI 201335) (Company: Boehringer Ingelheim)

5.2.1 Phase I

5.2.2 Phase II

5.2.3 Phase III

5.3 Asunaprevir (BMS-650032) (Company: Bristol-Myers Squibb)

5.3.1 Phase I

5.3.2 Phase II

5.3.3 Phase III

5.4 Sofosbuvir (PSI-7977 or GS-7977) (Company: Gilead Sciences)

5.4.1 Phase II

5.4.2 Phase III

5.5 Daclatasvir (BMS-790052) (Company: Bristol-Myers Squibb)

5.5.1 Phase II

5.5.2 Phase III

5.6 BI-207127 (Company: Boehringer Ingelheim)

5.6.1 Phase I

5.6.2 Phase II

5.6.3 Phase III

5.7 PEG-Interferon Lambda (Company: Bristol-Myers Squibb)

5.7.1 Phase I

5.7.2 Phase III

5.8 ABT-450/r (Ritonavir) (Company: Abbott Laboratories)

5.8.1 Phase I

5.8.2 Phase II

5.8.3 Phase III

5.9 ABT-267 (Company: Abbott Laboratories)

5.9.1 Phase II

5.9.2 Phase III

5.10 ABT-072/333 (Company: Abbott Laboratories)

5.10.1 Phase I

5.10.2 Phase II

5.10.3 Phase III

5.11 Alisporivir (Company: Novartis)

5.11.1 Phase II

5.11.2 Phase III

6. HEPATITIS C – PIPELINE DRUGS CLINICAL TRIALS (DRUGS IN PHASE II)**6.1 Mericitabine (RG-7128) (Company: Roche)**

6.1.1 Phase II

6.2 Danoprevir/r (Ritonavir) (RG7227) (Company: Roche)

6.2.1 Phase I

6.2.2 Phase II

6.3 GS-9256 (Company: Gilead Sciences)

6.3.1 Phase II

6.4 GS-9451 (Company: Gilead Sciences)

6.4.1 Phase II

6.5 MK-5172 (Company: Merck)

6.5.1 Phase I

6.5.2 Phase II

6.6 Sovaprevir (ACH-1625) (Company: Achillion)

6.6.1 Phase II

6.7 IDX-320 (Company: Idenix)

6.7.1 Phase I

6.8 MK-8742 (Company: Merck)

6.8.1 Phase I

6.8.2 Phase II

6.9 ACH-3102 (Company: Achillion Pharmaceuticals, Inc)

6.9.1 Phase I

6.9.2 Phase II

6.10 IDX-719 (Company: Idenix)

6.10.1 Phase I

6.10.2 Phase II

6.11 PPI-668 (Company: Presidio Pharmaceuticals)

6.11.1 Phase I

6.12 Setrobuvir (ANA-598) (Company: Roche)

6.12.1 Phase I

6.12.2 Phase II

6.13 VX-222 (Company: Vertex Pharmaceuticals)

6.13.1 Phase I

6.13.2 Phase II

6.14 GS-9669 (Company: Gilead Sciences)

6.14.1 Phase I

6.14.2 Phase II

6.15 GS-9190 (Tegobuvir) (Company: Gilead Sciences)

6.15.1 Phase II

6.16 BMS-791325 (Company: Bristol-Myers Squibb)

6.16.1 Phase II

7. HEPATITIS C - PIPELINE DRUGS SALES FORECAST

7.1 Simeprevir (TMC 435) Sales Forecast

7.2 Faldaprevir (BI 201335) (Boehringer Ingelheim) Sales Forecast

7.3 Asunaprevir (BMS-650032) Sales Forecast

7.4 Sofosbuvir (PSI-7977 or GS-7977) Sales Forecast

7.5 Daclatasvir (BMS-790052) Sales Forecast

7.6 ABT-450/r (Ritonavir) Sales Forecast

7.7 ABT-072/333 Sales Forecast

7.8 Alisporivir Sales Forecast

7.9 Mericitabine (RG-7128) Sales Forecast

7.10 Danoprevir (RG7227) Sales Forecast

7.11 GS-9256 Sales Forecast

7.12 Setrobuvir (ANA-598) Sales Forecast

7.13 VX-222 Sales Forecast

7.14 GS-9190 (Tegobuvir) Sales Forecast

7.15 BMS-791325 Sales Forecast

List Of Figures

LIST OF FIGURES:

- Figure 2 1: Global – Hepatitis C Drug Market (Million US\$), 2011 – 2012
- Figure 2 2: Global – Forecast for Hepatitis C Drug Market (Million US\$), 2013 – 2018
- Figure 3 1: Global – Pegasys Sales (Million US\$), 2005 – 2012
- Figure 3 2: Global – Forecast for Pegasys Sales (Million US\$), 2013 – 2016
- Figure 3 3: Global – Pegintron Sales (Million US\$), 2009 – 2012
- Figure 3 4: Global – Forecast for Pegintron Sales (Million US\$), 2013 – 2016
- Figure 3 5: Global – Incivek Sales (Million US\$), 2011 – 2012
- Figure 3 6: Global – Forecast for Incivek Sales (Million US\$), 2013 – 2016
- Figure 3 7: Global – Victrelis Sales (Million US\$), 2011 – 2012
- Figure 3 8: Global – Forecast for Victrelis Sales (Million US\$), 2013 – 2016
- Figure 7 1: Global – Forecast for Simeprevir (TMC 435) Sales (Million US\$), 2014 – 2018
- Figure 7 2: Global – Forecast for Faldaprevir (BI-201335) Sales (Million US\$), 2014 – 2018
- Figure 7 3: Global – Forecast for Asunaprevir (BMS-650032) Sales (Million US\$), 2015 – 2019
- Figure 7 4: Global – Forecast for Sofosbuvir (PSI-7977 or GS-7977) Sales (Million US\$), 2014 – 2018
- Figure 7 5: Global – Forecast for Daclatasvir (BMS-790052) Sales (Million US\$), 2015 – 2018
- Figure 7 6: Global – Forecast for ABT-450/r Sales (Million US\$), 2016 – 2019
- Figure 7 7: Global – Forecast for ABT-072/333 Sales (Million US\$), 2015 – 2019
- Figure 7 8: Global – Forecast for Alisporivir Sales (Million US\$), 2014 – 2019
- Figure 7 9: Global – Forecast for Meracitabine (RG-7128) Sales (Million US\$), 2015 – 2018
- Figure 7 10: Global – Forecast for Danoprevir Sales (Million US\$), 2015 – 2018
- Figure 7 11: Global – Forecast for GS-9256 Sales (Million US\$), 2015 – 2019
- Figure 7 12: Global – Forecast for Setrobuvir (ANA-598) Sales (Million US\$), 2015 – 2018
- Figure 7 13: Global – Forecast for VX-222 Sales (Million US\$), 2016 – 2018
- Figure 7 14: Global – Forecast for GS-9190 Sales (Million US\$), 2015 – 2019
- Figure 7 15: Global – Forecast for BMS-791325 Sales (Million US\$), 2015 – 2019

List Of Tables

LIST OF TABLES:

Table 4 1: Hepatitis C – Deals & Acquisitions in the anti-HCV Drug Space, 2004 – 2012

Table 5 1: Clinical Trial – ABT-450/r

I would like to order

Product name: Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide

Product link: <https://marketpublishers.com/r/H554E2B786AEN.html>

Price: US\$ 2,090.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H554E2B786AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

